48 results about "Infected cell" patented technology

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

Described herein are compositions and methods for reducing or eliminating latent herpes simplex virus type 2 (HSV-2) in HSV-2 infected cells, or for reducing or eliminating latent HSV-2 reactivation in HSV-2 infected cells, thereby providing viable therapeutic methods for latent HSV-2 infection. The compositions comprise a plurality of viral vectors, where the viral vectors comprise a sequence encoding a HSV-2 specific megasuclease. The method comprises delivering a plurality of one or more viral vectors to the HSV-2 infected cell, where each of the one or more viral vectors comprises a sequence encoding an HSV-2 specific megasuclease.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

The invention relates to an infectious arenavirus particle that is genetically engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but incapable of producing further infectious progeny particles in normal, non-genetically engineered cells.One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z, and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells, but still allow gene expression in arenavirus vector-infected cells, and foreign genes encoding an antigen or other protein of interest or nucleic acids that regulate host gene expression are expressed under the control of arenavirus promoters, internal ribosome entry sites, or under the control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II, or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Q), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a sdAb, wherein the sbAb inhibits the replication of viruses such as Ebola virus and Zika virus in infected cells.

The invention discloses a scorpion margaritae polypeptide with anti-EV71 virus activity and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The Buthus martensii Karsch polypeptide with the anti-EV71 virus activity is Pep 15 or Pep 16; the amino acid sequence of the Pep 15 is as shown in SEQ ID NO. 1; the amino acid sequence of the Pep16 is as shown in SEQ ID NO. 2. The obtained buthus martensii polypeptide has remarkable anti-EV71 virus activity, inhibits the cytopathic effect generated by EV71 virus on host cells Vero, increases the survival rate of infected cells and inhibits replication and proliferation of EV71 virus in cells, has no toxic effect on cells when the concentration of the buthus martensii polypeptide reaches 200 mu M, has the potential of being used as an anti-EV71 virus drug, and can be used as a drug for treating EV71 virus. The compound has a good application prospect in the aspect of developing a novel medicine for preventing and treating the hand-foot-and-mouth disease of infants induced by the EV71 virus.

The invention provides trispecific antibodies having one binding site binding to a target antigen on a cancer cell, pathogen, infected cell or autoreactive cell, and second and third binding sites binding to CD3 and CD28 respectively. Such antibodies can crosslink CD3 and CD28 on the surface of T cells at the cell-to-cell junction with target cells, and trigger CD3-mediated signal transduction (Signal 1) and costimulatory molecule-mediated signal transduction (Signal 2) for activation of T cells resulting in efficient elimination of target cells.

The application discloses a HER2 adenovirus and application thereof, and belongs to the technical field of adenovirus preparation. The application provides a novel HER2 specific chimeric antigen, and the nucleotide sequence is shown as SEQ ID NO. 19. The chimeric antigen is formed by inserting a CAR structure into an MCS region of an Ad5F35 type adenovirus vector, and the CAR structure is as follows: signal peptide + C-MYC + HER2scfv + hinge region + transmembrane region + CD3Z + FCER1G + CD19. The novel HER2 adenovirus can specifically target HER2 positive tumor cells, has a wide host range, has high infection efficiency, and can be used for infecting hematopoietic stem cells, dendritic cells, T cells, NK cells, K562, U937 and other difficult-to-transfect blood cells. The infected cells can rapidly express the adenovirus, the expression stability is high, the adenovirus cannot be integrated into host chromosomes, and the safety is good.

The invention provides the antibody specifically bound with the African swine fever virus CD2v protein and the application thereof, the antibody is high in titer and stable in property, can be bound with ASFV infected cells, and provides an important tool for ASFV detection, CD2v antigen or fragment detection and CD2v protein structure analysis.

The invention discloses application of alpha-hederin in preparation of a medicine for preventing or treating staphylococcus aureus infectious diseases, and belongs to the technical field of medicines. The staphylococcus aureus infectious disease is one of skin or soft tissue infection, pneumonia, osteoarthritis, mastitis, enteritis, endocarditis, urinary tract infection and enteritis. The medicine does not have an in-vitro direct sterilization function on sensitive and methicillin-resistant staphylococcus aureus, but can remarkably promote infected cells to remove thalli under a cell infection condition, so that the medicine plays a role in resisting sensitive and methicillin-resistant staphylococcus aureus infection by improving the anti-infection immune level of the cells.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present disclosure provides compositions and methods for inhibiting hepatitis B virus (HBV) in infected cells. Exemplary methods include contacting an infected cell with one or more agents that induce interferon regulatory factor 3 (IRF3) activation in the infected cell. In some embodiments, the one or more agents include a nucleic acid molecule containing a pathogen-associated molecular pattern (PAMP), a small molecule agent (e.g., a benzothiazole derivative molecule), or a combination thereof. In some embodiments, the methods further include contacting the infected cell with an NRTI. The methods can be in vivo methods of treating a subject having an HBV infection, which include administering a therapeutically relevant amount of one or more agents formulated in one or more therapeutically effective compositions. Exemplary compositions are formulated for treating a hepatitis B virus (HBV) infection in a subject, which include: a RIG-I agonist, a vehicle for intracellular delivery, and a pharmaceutically acceptable carrier.

A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

The invention discloses a Griffithsin-IL18 fusion protein and a preparation method and application thereof.The Griffithsin-IL18 fusion protein comprises a Griffithsin protein fragment, an IL18 protein fragment and a flexible connecting peptide connecting the Griffithsin protein fragment and the IL18 protein fragment, the Griffithsin protein fragment is located at the N end of the fusion protein, and the IL18 protein fragment is located at the C end of the fusion protein. According to the present invention, the dual functions of virus infection blocking and immune activation are achieved, the Griffithsin fragment is specifically combined with host cell surface integrin to induce internalization and block virus endocytosis, and the IL-18 fragment activates NK cells so as to improve the overall antiviral efficiency and achieve the precise targeting intervention on the infected cells.

Multi-drug resistant tuberculosis (TB) is a major public health problem concerning about half a million cases each year. Patients hardly adhere to the current strict treatment consisting of more than 10,000 tablets over a 2-year period. There is a clear need for efficient and better-formulated medications. The inventors have previously shown that nanoparticles made of cross-linked poly-β-cyclodextrins (pβCD) are efficient vehicles for pulmonary delivery of powerful combinations of anti-TB drugs. Here, they report that in addition to be efficient drug carriers, pβCD nanoparticles are endowed with intrinsic antibacterial properties. Indeed, empty pβCD are able to impair M. tuberculosis (Mtb) establishment after pulmonary administration in mice. pβCD hamper colonisation of macrophages by Mtb by interfering with lipid rafts, without inducing toxicity. Moreover, pβCD provoke macrophage apoptosis leading to depletion of infected cells, thus creating a lung micro-environment detrimental to Mtb persistence. Taken together, the results suggest that materials made of cross-linked β-cyclodextrins (e.g. nanoparticles) loaded or not with antibiotics play an antibacterial action by its own and could be used as carrier in drug regimen formulations effective against TB.

A conjugate compound comprising (i) a ligand of a protein targeting RSV or RSV-infected cells, (ii) one or more linkers, and (iii) two or more haptens; a pharmaceutical composition comprising the conjugate compound; and a method of delivering the pharmaceutical agent to RSV or RSV-infected cells for therapeutic purposes.

Compositions and methods for treating HIV using compounds that sensitize HIV-1 infected cells to antibody-dependent cellular cytotoxicity.

The invention relates to application of miR-145-5P in preparation of a medicine for preventing and / or treating PRV (pseudorabies virus) infection related diseases, and belongs to the field of biological medicines. The miR-145-5p is found to be a key differential expression molecule in the PRV infected piglet lung and colon tissue exosome through high-throughput sequencing for the first time. In-vitro cell experiments prove that up-regulation of the expression of the miR-145-5p can significantly play an antiviral role through double mechanisms of inhibiting PRV virus replication and promoting apoptosis of infected cells, and research results of the invention provide a brand new target and strategy for prevention and treatment of PRV.

The present invention provides the use of a PNA oligomer comprising a modified PNA for the prevention or treatment of coronavirus infectious diseases. The PNA oligomer of the present invention can be delivered into a virus-infected cell without a delivery vehicle and inhibits viral proliferation, and thus does not have side effects caused by a delivery vehicle for increasing cell permeability of a conventional drug, and can be used as a target-specific drug due to its high binding affinity. Virus proliferation can be inhibited by binding to a target even if there is a mismatch. Therefore, it is expected that the PNA oligomer will be used as an effective coronavirus therapeutic agent that can respond to rapidly mutated viral infectious diseases.

The present invention provides an adeno-associated virus (AAV) vector and use thereof. The AAV vector comprises a nucleic acid fragment encoding a secreted tat-degradation peptide. The AAV vector designed in the present invention can be continuously expressed in the peripheral nervous system, where the expressed degradation peptides can cross the blood-brain barrier and cell membranes to exert long-term therapeutic effects in central nervous system (CNS) diseases. Additionally, the vector can also be continuously expressed in the CNS, where the degradation peptides cross the cell membrane to mediate its effects in both AAV-infected and non-infected cells. Therefore, the present invention offers an AAV vector that enables widespread and long-acting delivery of a therapeutic degradation peptide.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The invention provides the antibody specifically bound with the African swine fever virus CD2v protein and the application thereof, the antibody is high in titer and stable in property, can be bound with ASFV infected cells, and provides an important tool for ASFV detection, CD2v antigen or fragment detection and CD2v protein structure analysis.

The present application belongs to the field of biomedical technology, and relates to a biological preparation capable of effectively inhibiting porcine delta coronavirus. The core effective component of the biological preparation is fly maggot protein peptide. The fly maggot protein peptide is prepared by short-time heat treatment of fly maggot protein, three-stage directional enzymolysis of alkaline protease-trypsin-flavor protease, 500-3000 Da membrane fractionation and weak cation exchange enrichment. Experimental results show that the fly maggot protein peptide can significantly reduce the N gene expression level, N protein expression level and infectious virus titer in PDCoV infected cells, has obvious direct inhibitory effect on PDCoV infection, and has certain preventive effect on infection. Compared with ordinary enzymolysis products, the 500-3000 Da cation peptide component obtained by the present application has significant anti-PDCoV activity, and can be used for preparing veterinary drugs or biological preparations for inhibiting PDCoV infection.

The invention provides a bispecific antibody specifically combined with hepatitis B surface antigen and application thereof, and belongs to the technical field of chronic hepatitis B treatment and prevention. The bispecific antibody specifically bound with the hepatitis B surface antigen comprises a first antibody, and the first antibody is obtained by connecting a humanized anti-HBsAg antibody 2H5 heavy chain variable region and a light chain variable region with a human IgG1 heavy chain constant region and a light chain constant region respectively and mutating an Fc segment of the human IgG1 heavy chain constant region; the second antibody is obtained by connecting the 125S heavy chain variable region of the humanized anti-HBsAg antibody with the Fc segment of the heavy chain constant region of the human IgG1 and mutating the Fc segment of the heavy chain constant region of the human IgG1. The bispecific antibody is combined with two virus epitopes at the same time, so that immune escape is avoided; the neutralizing capability on viruses and the killing capability on infected cells are enhanced, and the two are cooperated to eliminate infection.

The invention provides trispecific antibodies having one binding site binding to a target antigen on a cancer cell, pathogen, infected cell or autoreactive cell, and second and third binding sites binding to CD3 and CD28 respectively. Such antibodies can crosslink CD3 and CD28 on the surface of T cells at the cell-to-cell junction with target cells, and trigger CD3-mediated signal transduction (Signal 1) and costimulatory molecule-mediated signal transduction (Signal 2) for activation of T cells resulting in efficient elimination of target cells.